Why the study?
Current therapies for cardiac AL and ATTR do not address mechanisms of tissue dysfunction because they remain unknown, and prior plaque proteome studies may not capture tissue-wide alterations.
What are the tissue-wide proteomic alterations and mechanisms of tissue damage in cardiac ATTR and AL amyloidosis?
What are the tissue-wide proteomic alterations and mechanisms of tissue damage in cardiac ATTR and AL amyloidosis?
Full biopsy tissue proteomics reveals immune-mediated mechanisms of tissue toxicity, particularly upregulated complement pathways, in cardiac amyloidosis patients with worse outcomes.
Tissue-wide proteomics reveals distinct pathway signatures in ATTR and AL; hypothesis-generating for immune-targeted studies in cardiac amyloidosis.
BACKGROUND: Cardiac AL and ATTR are potentially fatal cardiomyopathies. Current therapies do not address mechanisms of tissue dysfunction because these remain unknown. Our prior work focused on the amyloid plaque proteome, which may not capture tissue-wide proteomic alterations. OBJECTIVES: To evaluate mechanisms of tissue dysfunction in cardiac AL and ATTR using a full biopsy tissue proteomics approach. METHODS: We performed proteomics analysis on 76 ATTR and 27 AL diagnostic endomyocardial biopsies. RESULTS: stages-1/2, with decreased healthy cardiac metabolism. In stages-2 and 3 ATTR, immunoglobulin proteins, complement, and keratinisation pathways were increased compared to stage-1. Unsupervised analyses identified an ATTR group with worse survival characterised by upregulated complement and downregulated metabolic pathways. Compared to ATTR, AL had higher clathrin-mediated endocytosis, mRNA splicing, and ribosomal proteins, while ATTR had higher complement levels. CONCLUSIONS: This study identifies known processes dysregulated in heart failure with preserved ejection fraction as well as novel pathways responsible for tissue damage. Our results support an immune-mediated mechanism of tissue toxicity in cardiac amyloidosis, especially among patients with worse outcomes.
No takes yet. Share an insight, caveat, or question.
Netzel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: